TransMedics Group (NASDAQ:TMDX) Trading Down 5.5% – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) fell 5.5% during mid-day trading on Monday . The stock traded as low as $83.77 and last traded at $83.56. 209,361 shares traded hands during trading, a decline of 80% from the average session volume of 1,043,676 shares. The stock had previously closed at $88.43.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Stifel Nicolaus lifted their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Wall Street Zen cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 6th. Finally, Needham & Company LLC reduced their target price on TransMedics Group from $142.00 to $106.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TransMedics Group has a consensus rating of “Hold” and an average price target of $124.18.

TransMedics Group Stock Performance

The company has a fifty day moving average of $79.04 and a two-hundred day moving average of $93.59. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of 21.38 and a beta of 1.90. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million for the quarter, compared to analyst estimates of $184.00 million. During the same period in the prior year, the business posted $0.92 EPS. The firm’s quarterly revenue was up 20.7% compared to the same quarter last year. As a group, equities research analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

A number of large investors have recently added to or reduced their stakes in TMDX. Parallel Advisors LLC boosted its position in TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after acquiring an additional 83 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock valued at $277,000 after purchasing an additional 88 shares in the last quarter. HighPoint Advisor Group LLC boosted its position in shares of TransMedics Group by 3.1% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after purchasing an additional 88 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in TransMedics Group by 2.9% during the second quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares during the period. Finally, US Bancorp DE increased its holdings in TransMedics Group by 24.2% in the third quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after purchasing an additional 104 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.